Nutritional management of cystic fibrosis

Journal of Parenteral and Enteral Nutrition

Volumn 36, Issue 1 SUPPL., 2012, Pages

  Matel, Julia L ^a,b  

^a LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^b 725 Welch Road ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; COLECALCIFEROL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; PANCRELIPASE; PANCRELIPASEA; RETINOL; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN K GROUP;

ALPHA TOCOPHEROL DEFICIENCY; BODY MASS; CONFERENCE PAPER; CYSTIC FIBROSIS; DIET THERAPY; ENERGY EXPENDITURE; ENZYME REPLACEMENT; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALABSORPTION; NUTRITION; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; PRIORITY JOURNAL; QUALITY OF LIFE; RETINOL DEFICIENCY; VITAMIN D DEFICIENCY; VITAMIN K DEFICIENCY; VITAMIN SUPPLEMENTATION; ARTICLE; METHODOLOGY; NUTRITIONAL DISORDER; NUTRITIONAL REQUIREMENT;

CYSTIC FIBROSIS; HUMANS; NUTRITION DISORDERS; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; NUTRITIONAL REQUIREMENTS; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT;

EID: 84860579742     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607111420156     Document Type: Conference Paper

References (63)

1. Cystic Fibrosis Foundation. About cystic fibrosis. http://www.cff. org/About CF/. Published 2009. Accessed May 31, 2011.
2. Davies JC, Alton EWFW, Bush A. Cystic fibrosis. BMJ. 2007;335:1255-1259.
3. Davies PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med. 1996;154:1229-1256.
4. Corey M, McLaughlin FJ, Williams M, et al. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol. 1988;41:583-591.
5. Cystic Fibrosis Foundation patient data registry. Bethesda, MD: Cystic Fibrosis Foundation; 2009.
6. Konstan MW, Butler SM, Wohl MEB, et al. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr. 2003;142:624-630.
7. Littlewood JM, Wolfe SP, Conway SP. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr Pulmonol. 2006;41:35-49.
8. Robinson PJ, Smith AL, Sly PD. Duodenal pH in cystic fibrosis and its relationship to fat malabsorption. Dig Dis Sci. 1990;35: 1299-1304.
9. Bell SC, Bowerman AM, Nixon LE, Macdonald IA, Elborn JS, Shale DJ. Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis. Eur J Clin Invest. 2000;30:553-559.
10. Dorlöchter L, Røksund O, Helgheim V, Rosendahl K, Fluge G. Resting energy expenditure and lung disease in cystic fibrosis. J Cyst Fibros. 2002;1:131-136.
11. Girardet JP, Tounian P, Sardet A, et al. Resting energy expenditure in infants with cystic fibrosis. J Pediatr Gastroenterol Nutr. 1994;18:214-219.
12. Thomson MA, Wilmott RW, Wainwright C, Masters B, Francis PJ, Shepherd RW. Resting energy expenditure, pulmonary inflammation, and genotype in the early course of cystic fibrosis. J Pediatr. 1996;129:367-373.
13. Feigal RJ, Shapiro BL. Mitochondrial calcium uptake and oxygen consumption in cystic fibrosis. Nature. 1979;278:276-277.
14. Bronstein MN, Davies PS, Hambidge KM, Accurso FJ. Normal energy expenditure in the infant with presymptomatic cystic fibrosis. J Pediatr. 1995;126:28-33.
15. Bines JE, Truby HD, Armstrong DS, Phelan PD, Grimwood K. Energy metabolism in infants with cystic fibrosis. J Pediatr. 2002;140:527-533.
16. Fried MD, Durie PR, Tsui LC, Corey M, Levison H, Pencharz PB. The cystic fibrosis gene and resting energy expenditure. J Pediatr. 1991;119:913-916.
17. Kalivianakis M, Minich DM, Bijleveld CMA, van Aalderen WMC, Stellaard F, Laseur M. Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long-chain fatty acids. Am J Clin Nutr. 1999:69:127-134.
18. Borowitz D, Robinson K, Rosenfeld M, et al. Cystic fibrosis foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr. 2009; 155:S73-93.
19. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002;35:246-259.
20. Subcommittee on the Tenth Edition of the RDAs, Food and Nutrition Board, Commission on Life Sciences, National Research Council. Recommended Dietary Allowances. 10th ed. Washington, DC; National Academy Press; 1989.
21. Maqbool A, Stallings VA. Update on fat-soluble vitamins in cystic fibrosis. Curr Opin Pulm Med. 2008;14:574-581.
22. Maqbool A, Graham-Maar RC, Schall JL, et al. Vitamin A intake and elevated serum retinol levels in children and young adults with cystic fibrosis. Am J Clin Nutr. 2008;7:137-141.
23. Holick MF. The vitamin D epidemic and its health consequences. J Nutr. 2005;135:2739S-2748S.
24. Looker AC, Dawson-Hughes B, Calvo MS, et al. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone. 2002;30:771-777.
25. Rovner AJ, O'Brien KO. Hypovitaminosis D among healthy children in the United States: a review of the current evidence. Arch Pediatr Adolesc Med. 2008;162:513-519.
26. Stephenson A, Brotherwood M, Robert R, et al. Cholecalciferol significantly increases 25-hydroxyvitamin D concentrations in adults with cystic fibrosis. Am J Clin Nutr. 2007;85:1307-1311.
27. Rovner AJ, Stallings VA, Schall JL, et al. Vitamin D insufficiency in children, adolescents, and young adults with cystic fibrosis despite routine oral supplementation. Am J Clin Nutr. 2007;86:1694-1699.
28. Haworth CS, Selby PL, Webb AK, et al. Low bone mineral density in adults with cystic fibrosis. Thorax. 1999;54:961-967.
29. Aris RM, Merkel PA, Bachrach LK. Consensus statement: guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab. 2005;90:1888-1896.
30. Boyle MP, Noschese ML, Watts SL, et al. Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis. Am J Respir Crit Care Med. 2005;172:212-217.
31. 3 in humans. J Clin Endocrinol Metab. 2004;89:5387-5391.
32. 2. Am J Clin Nutr. 1998;68:854-858.
33. Khazai NB, Judd SE, Jeng L, et al. Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol and UV light. J Clin Endocrinol Metab. 2009;94:2037-2043.
34. 2 therapy in pediatric cystic fibrosis patients. J Cyst Fibros. 2010;9:143-149.
35. Sathe MN, Patel AS. Update in pediatrics: focus on fat-soluble vitamins. Nutr Clin Pract. 2010;25:340-346.
36. Boas SR, Hageman JR, Ho LT, Liveris M. Very high-dose ergocalciferol is effective for correcting vitamin D deficiency in children and young adults with cystic fibrosis. J Cyst Fibros. 2009;8: 270-272.
37. Carr SB, McBratney J. The role of vitamins in cystic fibrosis. J R Soc Med. 2000;93(suppl 38):14-19.
38. Wilfond BS, Farrell PM, Laxova A, et al. Severe hemolytic anemia associated with vitamin E deficiency in infants with cystic fibrosis: implications for neonatal screening. Clin Pediatr. 1994; 33:2-7.
39. Willison HG, Muller DPR, Matthews S, et al. A study of the relationship between neurological function and serum vitamin E concentrations in patients with cystic fibrosis. J Neurol Neurosurg Psychiatry. 1985;48:1097-1102.
40. Sitrin MD, Lieberman F, Jensen WE, et al. Vitamin E deficiency and neurologic disease in adults with cystic fibrosis. Ann Intern Med. 1987;107:51-54.
41. Cynamon HA, Milov DE, Valenstein E, Wagner M. Effect of vitamin E deficiency on neurologic function in patients with cystic fibrosis. J Pediatr. 1988;113:637-640.
42. Horwitt MK, Harvey CC, Dahm CH Jr, Searcy MT. Relationship between tocopherol and serum lipid levels for determination of nutritional adequacy. Ann N Y Acad Sci. 1972;203:223-236.
43. Thurnham DI, Davies JA, Crump BJ, et al. The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. Ann Clin Biochem. 1986;23(pt 5):514-20.
44. James DR, Alfaham M, Goodchild MC. Increased susceptibility to peroxide-induced haemolysis with normal vitamin E concentrations in cystic fibrosis. Clin Chim Acta. 1991;204:279-290.
45. Motta MEFA, Starling ALP, Penna FJ. Nutritional care in childhood cholestasis. Int Pediatr. 1999;14:213-220.
46. Ramaccioni V, Soriano HE, Arumugum R, et al. Nutritional aspects of chronic liver disease and liver transplantation in children. J Pediatr Gastroenterol Nutr. 2000;30:361-367.
47. Durie PR. Vitamin K and the management of patients with cystic fibrosis. CMAJ. 1994;151:933-936.
48. Dougherty KA, Schall JI, Stallings VA. Suboptimal vitamin K status despite supplementation in children and young adults with cystic fibrosis. Am J Clin Nutr. 2010;92:660-667.
49. Schwarzenberg SJ, Wielinski CL, Shamieh BLM, et al. Cystic fibrois-associated colitis and fibrosing colonopathy. J Pediatr. 1995;127:565-570.
50. Anelli M, Foresti R, Peloso L, Ortenzi G. Overfilling in current pancreatic enzyme preparations (PEPs): still an unresolved issue. Pediatr Pulmonol. 2007;42:391.
51. Case CL, Henniges F, Barkin JS. Enzyme content and acid stability of enteric coated pancreatic enzyme products in vitro. Pancreas. 2005;30:180-183.
52. Walters MP, Littlewood JM. Pancreatin preparations used in the treatment of cystic fibrosis-lipase content and in vitro release. Aliment Pharmacol Ther. 1996;10:433-440.
53. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: exocrine pancreatic insufficiency frug products-submitting NDAs. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm071651.pdf. Accessed May 31, 2011.
54. Littlewood JM, Wolfe SP, Conway SP. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr Pulmonol. 2006;41:35-49.
55. Butt AM, Ip W, Ellis L, et al. The fate of ingested enzymes in cystic fibrosis. Pediatr Pulmonol. 2001;22(suppl):137-138.
56. Ng SM, Jones AP. Drug therapies for reducing gastric acidity in people with cystic fibrosis. Cochrane Database Syst Rev. 2003;2: CD003424.
57. Francisco MP, Wagner MH, Sherman JM, et al. Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002;35:79-83.
58. Erskine JM, Lingard CD, Sontag MK, et al. Enteral nutrition for patients with cystic fibrosis: comparison of a semi-elemental and nonelemental formula. J Pediatr. 1998;132:265-269.
59. Conway SP, Morton A, Wolfe S. Enteral tube feeding for cystic fibrosis. Cochrane Database Syst Rev. 2008;2:CD001198.
60. Williams SGJ, Ashworth F, McAlweenie A, Poole S, Hodson ME, Westaby D. Percutaneous endoscopic gastrostomy feeding in patients with cystic fibrosis. Gut. 1999;44:87-90.
61. Efrati O, Mei-Zahav M, Rivlin J, et al. Long term nutritional rehabilitation by gastrostomy in Israeli patients with cystic fibrosis: clinical outcome in advanced pulmonary disease. J Pediatr Gastroenterol Nutr. 2006;42:222-228.
62. Van Biervliet S, DeWaele K, Van Winckel M, Robberecht E. Percutaneous endoscopic gastrostomy in cystic fibrosis: patient acceptance and effect of overnight tube feeding on nutritional status. Acta Gastroenterol Belg. 2004;67:241-244.
63. Oliver MR, Heine RG, Ng CH, Volders E, Olinsky A. Factors affecting clinical outcome in gastrostomy-fed children with cystic fibrosis. Pediatr Pulmonol. 2004;37:324-329.